TOP NEWS

Juno Therapeutics, Novartis Settle Patent Dispute

Seattle-based Juno Therapeutics has settled patent litigation between the company and Novartis, the two said Monday morning. According to the two, Novartis agreed to pay $12.25M plus future milestone and "mid-single digit" royalties to Juno for use of U.S. Patent 8,399,645. Both companies have been working on cancer tumor treatments based on the patent, originally issued to St. Jude Children's Research Hospital. The two have been fighting over a contract dispute involving those patents since 2012.


LATEST HEADLINES

More Headlines

BROWSE ISSUES